Biotech Values

[rwdm]

Teva's official PR is the following:
Jerusalem, September 21, 2010 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today it has filed a complaint in the U.S. District Court for the Southern District of New York against Mylan asserting infringement of four patents related to the characterization of COPAXONE® (glatiramer acetate injection). The latest of these patents expires in February 2020.

Teva previously filed a separate lawsuit against Mylan in October 2009 for infringement of multiple patents, including all seven Orange Book patents, covering the chemical composition of COPAXONE®, pharmaceutical compositions containing it, methods of using it and processes for making it. Those patents expire in May 2014 and September 2015. No trial date is scheduled.

In fact, Teva sued Mylan on the infringement of 9 patents (7 from the Orange Book and 2 additional patents). One of these additional patents (US5800808) expires in September 2015.